ADMS News and Press, Adamas Pharmaceuticals Inc. From 01/02/20

EMERYVILLE, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that it has entered into a ...

Adamas Pharmaceuticals ( ADMS ) publicized their INROADS study in multiple sclerosis “MS” patients with walking impairment met its primary endpoint but missed on its secondary endpoints. The results exhibited that patients taking 274 mg of GOCOVRI had a statistically significant ...

New York, New York--(Newsfile Corp. - December 17, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) ("Adamas" or the "Company") of the February 10, 2020 deadline to seek the role of lead plaintiff in a fe...

Gainers:  Kaixin Auto (NASDAQ: KXIN ) +32% . More news on: Kaixin Auto Holdings, NantKwest, Inc., Renewable Energy Group, Inc., Stocks on the move, Read more ...

Adamas Pharmaceuticals ( ADMS -39.9% ) slumps on a 5x surge in volume as investors scrutinize the Phase 3 results on Gocovri (amantadine) released this morning. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

"As we did not see the scale of clinical benefit we had hoped for in this study we will fully assess the potential for ADS-5102 in MS patients before determining the extent of our continued investment in this program," says Adamas ( ADMS -40.7% ) CEO Neil McFarlane after mixed results in...

Adamas Pharmaceuticals (NASDAQ: ADMS ) announces positive results from a Phase 3 clinical trial, INROADS , evaluating Gocovri (amantadine) (ADS-5102) in multiple sclerosis (MS) patients with walking impairment. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks o...

- INROADS study achieved its primary endpoint (proportion of responders with at least a 20% improvement from baseline to Week 12) - - Dose-response observed for both efficacy and safety - - Safety data consistent with known safety profile of amantadine - EMERYVILLE, Calif., De...

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS ) investors concerning the Company and its officers’ possible violations of federal securiti...

Adamas Pharmaceuticals ( ADMS ) has taken numerous steps to proliferate GOCOVRI adoption and the numbers are slowly grinding higher. The company’s third-quarter product sales came in a $13.9M, which was a 9% increase over Q2 and a 31% increase over Q3 of last year. Thus far, GOCOVRI h...